An Engineered IgG–VHH Bispecific Antibody against SARS‐CoV‐2 and Its Variants (Small Methods 12/2022)

An Engineered IgG–VHH Bispecific Antibody against SARS‐CoV‐2 and Its Variants (Small Methods 12/2022)

Front Cover In article number 2200932, Lang, Shao, Deng, Wang, Qin, and co‐workers designed and developed a novel bispecific antibody (bsAb), which combines the strengths of IgG and nanobody, and comprehensively characterized its potency to block SARS‐CoV‐2 and its variants in vitro and in vivo. Thi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Small methods 2022-12, Vol.6 (12), p.n/a
Hauptverfasser: Chi, Hang, Wang, Lei, Liu, Chanjuan, Cheng, Xiaohe, Zheng, Hailiang, Lv, Lilang, Tan, Yongcong, Zhang, Nana, Zhao, Suoqun, Wu, Mei, Luo, Dan, Qiu, Hongying, Feng, Rui, Fu, Wangjun, Zhang, Jie, Xiong, Xiaochuan, Zhang, Yifei, Zu, Shulong, Chen, Qi, Ye, Qing, Yan, Xintian, Hu, Yuhao, Zhang, Zhen, Yan, Run, Yin, Jiangfeng, Lei, Pan, Wang, Wanjing, Lang, Guojun, Shao, Junbin, Deng, Yongqiang, Wang, Xiangxi, Qin, Chengfeng
Format: Artikel
Sprache:eng
Schlagworte:
bispecific antibody
IgG
novel format
SARS‐CoV‐2
VHH
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Front Cover In article number 2200932, Lang, Shao, Deng, Wang, Qin, and co‐workers designed and developed a novel bispecific antibody (bsAb), which combines the strengths of IgG and nanobody, and comprehensively characterized its potency to block SARS‐CoV‐2 and its variants in vitro and in vivo. This universal bsAb platform provides an effective and promising tool for the development of therapeutics against COVID‐19 as well as other diseases.
ISSN:2366-9608
2366-9608
DOI:10.1002/smtd.202270068